MS and Demyelinating Disorders

New biomarkers of disease activity may help better vet investigational therapies aimed at slowing the insidious neurodegeneration seen in primary progressive multiple sclerosis.

Neurology News Network for the week ending August 29, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 28, 2020.

A group of international experts in the treatment of multiple sclerosis offer their varying viewpoints on the history, identification, and management of the disease.

Neurology News Network for the week ending August 22, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 21, 2020.

Novartis’ anti-CD20 monoclonal antibody ofatumumab (Kesimpta) is administered once monthly at home, and is expected to be available for those with multiple sclerosis as early as September 2020.

The subcutaneous injection is indicated in patients with anti-aquaporin-4 antibody positive NMOSD.

Neurology News Network for the week ending August 15, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 14, 2020.

Larger social network effective size correlated with better physical function, while network constraint correlated with worse physical function in those with multiple sclerosis.

A cohort study showed that those with relapse activity who received DMTs accounted for a greater percent of time with a reduced Multiple Sclerosis Severity Score progression slope during SPMS.

The full data from the ASCLEPIOS I and II trials suggest that the Novartis agent ofatumumab is superior to teriflunomide in reducing annualized relapse rates and other measurements of disease progression in MS.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 7, 2020.

An overview of the tweet chat on mental health in neurological disorders, featuring highlighted contributions from the medical community.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 31, 2020.

The program will include video presentations of the Platform Abstracts covering the latest MS research as well as a CMSC Business Meeting with the winners of the International Journal of MS named.

The findings indicate that the use of a MS severity score (Ped-MSSS) model may provide an alternative to EDSS scoring, which has been shown to be lower in pediatric disease, in clinical assessment of disease severity and disability accrual.

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the benefit that physicians and patients can be provided by highly selective S1P modulators in MS treatment.

Join NeurologyLive and the Women Neurologist Group on Twitter to discuss the importance of mental health and wellness in neurologic disorders.